Benitec Biopharma Inc. (BNTC) Stock Price & Analysis
Benitec Biopharma Inc. (BNTC) rose 2.95% to USD 10.81 as of June 10, 2026 at 05:34 UTC, according to Nexqual real-time market data.
BNTC last closed at USD 10.5; the session ranged USD 10.51–11 on volume of 89,647 shares. Market capitalization is $371.37M, with a 52-week range of USD 9.85–17.11 (NCM). Source: Nexqual, June 10, 2026 at 05:34 UTC.
Key Statistics (as of June 10, 2026 at 05:34 UTC)
| Price | USD 10.81 |
|---|---|
| Change | ▲ 2.95% (up) |
| Previous Close | USD 10.5 |
| Open | USD 10.57 |
| Day Range | USD 10.51 – 11 |
| 52-Week Range | USD 9.85 – 17.11 |
| Volume | 89,647 shares |
| Market Cap | $371.37M |
| Exchange | NCM |
Technical Analysis (BNTC)
Nexqual's technical model rates BNTC "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.21 (neutral) |
| vs SMA50 | Below (USD 11.73) |
| MACD | -0.35 (negative) |
Analyst Ratings (BNTC)
Wall Street analysts rate BNTC "None" based on 6 analysts, with a mean price target of USD 24.33 (range USD 17–32), per Nexqual as of June 10, 2026 at 05:34 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 24.33 |
| High Target | USD 32 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (BNTC)
| Next Earnings Date | 2026-05-14 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.24 vs est -0.28 ▲ beat |
| 2025-12-31 | USD -0.26 vs est -0.23 ▼ miss |
| 2025-09-30 | USD -0.22 vs est -0.36 ▲ beat |
| 2025-06-30 | USD -0.42 vs est -0.31 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:34 UTC.
Financials & Fundamentals (BNTC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -29.58% |
| Debt / Equity | 0.48 |
| Current Ratio | 56.82 |
| Total Cash | $184.76M |
| Total Debt | $876,000 |
| Free Cash Flow | $-7.13M |
Source: Nexqual, June 10, 2026 at 05:34 UTC.
Financial Health Score (BNTC)
Nexqual rates Benitec Biopharma Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:34 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $185M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$20M |
| Efficiency | Critical — ROE -30%, ROA -19.9% |
Ownership (BNTC)
| Insider Ownership | +2.70% |
|---|---|
| Institutional Ownership | +98.25% |
| Shares Outstanding | 34.35M |
| Float | 17.87M |
| Short % of Float | +12.01% |
Source: Nexqual, June 10, 2026 at 05:34 UTC.
Leadership (BNTC)
Benitec Biopharma Inc. is led by Jerel A. Banks (age 49), Executive Chairman & CEO, per Nexqual as of June 10, 2026 at 05:34 UTC.
| Executive Chairman & CEO | Jerel A. Banks (age 49) |
|---|---|
| CFO & Secretary | Megan Joan Boston B.Com., C.A. (age 52) |
| Chief Operating Officer | Sophie Mukadam (age 44) |
| Senior Vice President of Manufacturing | Claudia Kloth |
Major Backers & Investors (BNTC)
Notable institutional backers of Benitec Biopharma Inc. include Suvretta Capital Management, LLC, Janus Henderson Group PLC, Franklin Resources, Inc., according to Nexqual as of June 10, 2026 at 05:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 33.62% |
| Janus Henderson Group PLC | 8.37% |
| Franklin Resources, Inc. | 6.92% |
| Adage Capital Partners GP L.L.C. | 6.17% |
| RA Capital Management, L.P. | 5.39% |
| Nantahala Capital Management, LLC | 4.19% |
| Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | 3.07% |
| Infinitum Asset Management, LLC | 2.69% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.57% |
| BlackRock | 5.16% |
Source: Nexqual, June 10, 2026 at 05:34 UTC.
From Benitec Biopharma Inc.'s Latest SEC 10-K Filing (filed 2025-09-22)
Key Strengths & Strategy (as disclosed to the SEC)
- Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
- Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
- The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PULM | Pulmatrix, Inc. | USD 1.38 | ▲ 3.76% |
| CBIO | Crescent Biopharma, Inc. | USD 18 | ▲ 0% |
| AKTX | Akari Therapeutics Plc | USD 15 | ▼ 0.46% |
| TENX | Tenax Therapeutics, Inc. | USD 10.73 | ▲ 0% |
| XBIO | Xenetic Biosciences, Inc. | USD 3.08 | ▼ 0.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:34 UTC. This page is informational and not investment advice.